

François Dupuis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113355/publications.pdf>

Version: 2024-02-01

17
papers

282
citations

933447

10
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

359
citing authors

#	ARTICLE	IF	CITATIONS
1	Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA™s nanoemulsions. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 305-312.	4.0	69
2	Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2005, 23, 1061-1066.	0.5	41
3	Captopril improves cerebrovascular structure and function in old hypertensive rats. <i>British Journal of Pharmacology</i> , 2005, 144, 349-356.	5.4	34
4	In Situ Microparticles Loaded with S-Nitrosoglutathione Protect from Stroke. <i>PLoS ONE</i> , 2015, 10, e0144659.	2.5	26
5	Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. <i>Journal of Hypertension</i> , 2010, 28, 1566-1573.	0.5	24
6	Impact of treatment with melatonin on cerebral circulation in old rats. <i>British Journal of Pharmacology</i> , 2004, 141, 399-406.	5.4	14
7	High salt intake abolishes AT2-mediated vasodilation of pial arterioles in rats. <i>Journal of Hypertension</i> , 2011, 29, 1392-1399.	0.5	12
8	Impact of Short-Term Treatment with Telmisartan on Cerebral Arterial Remodeling in SHR. <i>PLoS ONE</i> , 2014, 9, e110766.	2.5	11
9	Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 640-649.	4.3	10
10	No answer to the lack of specificity: mouse monoclonal antibody targeting the angiotensin II type 1 receptor AT1 fails to recognize its target. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 883-889.	3.0	10
11	Differential Effects of Short-Term Treatment with Two AT1 Receptor Blockers on Diameter of Pial Arterioles in SHR. <i>PLoS ONE</i> , 2012, 7, e42469.	2.5	9
12	S-nitrosoglutathione inhibits cerebrovascular angiotensin II-dependent and -independent AT ₁ receptor responses: A possible role of S-nitrosation. <i>British Journal of Pharmacology</i> , 2019, 176, 2049-2062.	5.4	6
13	Cerebral arteriolar structure and function in pinealectomized rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H1476-H1480.	3.2	5
14	Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6738.	4.1	4
15	In vivo and in silico evaluation of a new nitric oxide donor, S,S'-dinitrosobucillamine. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 71, 32-43.	2.7	3
16	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor- β and angiotensin II type 1 receptor. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 334-352.	5.5	3
17	Clinical and Organizational Impacts of Medical Ordering Settings on Patient Pathway and Community Pharmacy Dispensing Process: The Prospective ORDHOSPVILLE Study. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 2.	1.6	1